ロード中...
Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
Sodium glucose transporter 2 (SGLT2) inhibitors are a recently developed class of drug that have been approved for use in type 2 diabetes. Their unique extra-pancreatic glucuretic mode of action has encouraged their usage in type 1 diabetes as well. At the same time, reports of pseudo ketoacidosis a...
保存先:
| 出版年: | Indian J Endocrinol Metab |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Medknow Publications & Media Pvt Ltd
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4481661/ https://ncbi.nlm.nih.gov/pubmed/26180770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.157859 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|